Biological Process
| adult locomotory behavior | | IEA | Ensembl:ENSMUSP00000099446 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| cellular protein metabolic process | | TAS | | 2290271 | Reactome:REACT_17015 | Reactome | Reactome:REACT_17015 |
| digestive system development | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| endocrine pancreas development | | IEA | Ensembl:ENSMUSP00000099446 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| exploration behavior | | IEA | Ensembl:ENSMUSP00000099446 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| female pregnancy | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| long-term synaptic potentiation | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| memory | | IEA | Ensembl:ENSMUSP00000099446 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| positive regulation of cAMP-mediated signaling | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| positive regulation of glucagon secretion | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| positive regulation of glucose transport | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| positive regulation of insulin secretion | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| regulation of insulin secretion | | TAS | | 2290271 | Reactome:REACT_23974 | Reactome | Reactome:REACT_23974 |
| response to amino acid stimulus | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to axon injury | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to drug | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to glucose stimulus | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to organic cyclic compound | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to peptide hormone stimulus | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to selenium ion | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| response to starvation | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| sensory perception of pain | | IEA | Ensembl:ENSMUSP00000099446 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| signal transduction | | TAS | | 2290271 | PMID:2890159 | PINC | PMID:2890159 |
| triglyceride homeostasis | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
Cellular Component
| endoplasmic reticulum lumen | | TAS | | 2290271 | Reactome:REACT_23838 | Reactome | Reactome:REACT_23838 |
| endoplasmic reticulum lumen | | TAS | | 2290271 | Reactome:REACT_23843 | Reactome | Reactome:REACT_23843 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_17008 | Reactome | Reactome:REACT_17008 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_23981 | Reactome | Reactome:REACT_23981 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_23868 | Reactome | Reactome:REACT_23868 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_22268 | Reactome | Reactome:REACT_22268 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_22234 | Reactome | Reactome:REACT_22234 |
| extracellular region | | TAS | | 2290271 | Reactome:REACT_18392 | Reactome | Reactome:REACT_18392 |
| neuronal cell body | | IEA | Ensembl:ENSRNOP00000008481 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| secretory granule lumen | | TAS | | 2290271 | Reactome:REACT_23868 | Reactome | Reactome:REACT_23868 |
| secretory granule lumen | | TAS | | 2290271 | Reactome:REACT_23843 | Reactome | Reactome:REACT_23843 |
Molecular Function
| hormone activity | | IEA | UniProtKB-KW:KW-0372 | 2290271 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 |
| 1298468 | BP34_H | Blood pressure QTL 34 (human) | 2.16 | | Blood pressure | systolic | 17 | 623167 | 66547903 | Human |
| 1331651 | COPD12_H | Chronic obstructive pulmonary disease QTL 12 (human) | 2.44 | | Chronic airflow obstruction | post-bronchodilator FEV1/FVC | 17 | 10859378 | 66547903 | Human |
| 1559242 | FBRL6_H | Fibrinogen level QTL 6 (human) | 1.5 | | Fibrinogen level | | 17 | 10859378 | 80253028 | Human |
| 1559256 | SCL59_H | Serum cholesterol level QTL 59 (human) | 2.48 | | Lipid level | total cholesterol | 17 | 16064515 | 80253028 | Human |
| 2314737 | GLUCO88_H | Glucose level QTL 88 (human) | .62 | .01 | Glucose level | non-insulin dependent | 17 | 22006539 | 48006539 | Human |
| 2289219 | BW363_H | Body weight QTL 363 (human) | | .023 | Body fat amount | percent fat | 17 | 29807083 | 55807083 | Human |
| 1298510 | RA28_H | Rheumatoid arthritis QTL 28 (human) | | .0054 | Joint/bone inflammation | rheumatoid arthritis | 17 | 33673168 | 59673168 | Human |
| 1643409 | BW271_H | Body Weight QTL 271 (human) | 2.09 | .001 | Body weight | | 17 | 33673168 | 59673168 | Human |
| 2292948 | PRSTS109_H | Prostate tumor susceptibility QTL 109 (human) | 2.99 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292966 | PRSTS114_H | Prostate tumor susceptibility QTL 114 (human) | 3.85 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292975 | PRSTS112_H | Prostate tumor susceptibility QTL 112 (human) | 2.55 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292980 | PRSTS115_H | Prostate tumor susceptibility QTL 115 (human) | 1.7 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292987 | PRSTS116_H | Prostate tumor susceptibility QTL 116 (human) | 5.49 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292996 | PRSTS108_H | Prostate tumor susceptibility QTL 108 (human) | 2.52 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292997 | PRSTS113_H | Prostate tumor susceptibility QTL 113 (human) | 3.24 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2293010 | PRSTS111_H | Prostate tumor susceptibility QTL 111 (human) | 3.99 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292925 | PRSTS110_H | Prostate tumor susceptibility QTL 110 (human) | 3.15 | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292887 | PRSTS90_H | Prostate tumor susceptibility QTL 90 (human) | | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 2292890 | PRSTS84_H | Prostate tumor susceptibility QTL 84 (human) | | | Prostate tumor susceptibility | | 17 | 36784990 | 62784990 | Human |
| 1298421 | BP35_H | Blood pressure QTL 35 (human) | | .0001 | Blood pressure | hypertension susceptibility | 17 | 36852911 | 68465676 | Human |
| 2302768 | MAMTS25_H | Mammary tumor susceptibility QTL 25 (human) | | .01 | Mammary tumor susceptibility | | 17 | 36917829 | 62917829 | Human |
| 1643075 | BP89_H | Blood pressure QTL 89 (human) | 3.22 | .000059 | Blood pressure | | 17 | 38994411 | 72681088 | Human |
| 2292952 | PRSTS193_H | Prostate tumor susceptibility QTL 193 (human) | 4.51 | .0045 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292953 | PRSTS184_H | Prostate tumor susceptibility QTL 184 (human) | 5.82 | .0053 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292963 | PRSTS178_H | Prostate tumor susceptibility QTL 178 (human) | 6.18 | .0033 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292979 | PRSTS186_H | Prostate tumor susceptibility QTL 186 (human) | 5.75 | .0079 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292991 | PRSTS133_H | Prostate tumor susceptibility QTL 133 (human) | 2.56 | .01 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292999 | PRSTS179_H | Prostate tumor susceptibility QTL 179 (human) | 6.18 | .0033 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2293008 | PRSTS188_H | Prostate tumor susceptibility QTL 188 (human) | 6.06 | .0029 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292927 | PRSTS191_H | Prostate tumor susceptibility QTL 191 (human) | 4.13 | .0018 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292933 | PRSTS182_H | Prostate tumor susceptibility QTL 182 (human) | 5.44 | .0026 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2292944 | PRSTS180_H | Prostate tumor susceptibility QTL 180 (human) | 6.18 | .0065 | Prostate tumor susceptibility | | 17 | 40282159 | 66282159 | Human |
| 2289501 | BW444_H | Body weight QTL 444 (human) | 2.83 | | Body weight | BMI | 17 | 43331542 | 69331542 | Human |
| 2289511 | BW453_H | Body weight QTL 453 (human) | 2.15 | | Body fat amount | abdominal | 17 | 43331542 | 69331542 | Human |
| 1643462 | BW108_H | Body weight QTL 108 (human) | 2.24 | .0007 | Body fat amount | abdominal visceral | 17 | 46673110 | 72673110 | Human |